The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Roxana MehranPhillippe Gabriel StegMarc A PfefferKarola S JeringBrian Lee ClaggettEldrin F LewisChristopher B GrangerLars Valeur KøberAldo Pietro MaggioniDouglas L MannJohn Joseph Valentine McMurrayJean-Lucien RouleauScott D SolomonGregory DucrocqOtávio BerwangerCarmine G De PasqulaeUlf LandmesserMark Colquhoun PetrieDavid Sim Kheng LengPeter Van der MeerMartin LefkowitzYinong ZhouEugene BraunwaldPublished in: Circulation (2022)
gov; Unique identifier: NCT02924727.
Keyphrases
- acute myocardial infarction
- coronary artery disease
- percutaneous coronary intervention
- coronary artery
- phase iii
- study protocol
- angiotensin converting enzyme
- angiotensin ii
- clinical trial
- left ventricular
- phase ii
- open label
- binding protein
- acute coronary syndrome
- atrial fibrillation
- ejection fraction
- transcatheter aortic valve replacement